Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCQ908 phase 2 study in obesity and mixed dyslipidemia
2009-010198-19Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity and combined dyslipidaemia comparing LCQ908 with Placebo (2 arms). Primary endpoints: Change from baseline in HbA1c at 12 weeks, Weight loss efficacy and dose response and 1 more. Started Apr 2009; status: terminated.
02
Drugs
pradigastat
03
Conditions
obesitycombined dyslipidaemia
Beyond the preview
Go deeper on 2009-010198-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010198-19.